Name | Value |
---|---|
Revenues | 1.3M |
Cost of Revenue | 0.5M |
Gross Profit | 0.8M |
Operating Expense | 15.8M |
Operating I/L | -15.0M |
Other Income/Expense | -1.9M |
Interest Income | 0.7M |
Pretax | -16.9M |
Income Tax Expense | 0.2M |
Net Income/Loss | -17.1M |
Nyxoah S.A. is a medical technology company specializing in solutions for sleep disordered breathing conditions. Its flagship product, the Genio system, is a CE-Marked hypoglossal neurostimulation therapy designed to treat moderate to severe obstructive sleep apnea. The company generates revenue through the development and commercialization of its innovative medical devices, providing patients with a patient-centric approach to addressing their sleep apnea needs.